

# Paul R Rhomberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/860601/publications.pdf>

Version: 2024-02-01

114  
papers

5,051  
citations

71102

41  
h-index

98798

67  
g-index

114  
all docs

114  
docs citations

114  
times ranked

4202  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020). <i>Journal of Clinical Microbiology</i> , 2022, 60, e0244921.	3.9	9
2	Impact of COVID-19 on the antifungal susceptibility profiles of isolates collected in a global surveillance program that monitors invasive fungal infections. <i>Medical Mycology</i> , 2022, 60, .	0.7	13
3	Evaluation of Synergistic Activity of Isavuconazole or Voriconazole plus Anidulafungin and the Occurrence and Genetic Characterization of <i>Candida auris</i> Detected in a Surveillance Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	26
4	Comparative activity of posaconazole and systemic azole agents against clinical isolates of filamentous fungi from a global surveillance programme. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab088.	2.1	5
5	Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011â€“2019). <i>Journal of Antibiotics</i> , 2021, 74, 519-527.	2.0	9
6	In vitro activity of posaconazole and comparators versus opportunistic filamentous fungal pathogens globally collected during 8 years. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115473.	1.8	9
7	Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant <i>Candida parapsilosis</i> and <i>Candida tropicalis</i> and country-specific isolate dissemination. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105799.	2.5	61
8	Evaluation of Antimicrobial Effects of a New Polymyxin Molecule (SPR741) When Tested in Combination with a Series of Î²-Lactam Agents Against a Challenge Set of Gram-Negative Pathogens. <i>Microbial Drug Resistance</i> , 2020, 26, 319-328.	2.0	11
9	In Vitro Activity Analysis of a New Polymyxin, SPR741, Tested in Combination with Antimicrobial Agents against a Challenge Set of Enterobacteriaceae, Including Molecularly Characterized Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	3.2	5
10	Media for colistin susceptibility testing does not improve the detection of <i>Klebsiella pneumoniae</i> isolates carrying MgrB disruption and other mutation driven colistin resistance mechanisms. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 98, 115077.	1.8	4
11	Correlation between Broth Microdilution and Disk Diffusion Results when Testing Ceftazidime-Avibactam against a Challenge Collection of <i>Enterobacteriales</i> Isolates: Results from a Multilaboratory Study. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	5
12	Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018). <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	42
13	Activity of fosfomycin when tested against US contemporary bacterial isolates. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 93, 143-146.	1.8	16
14	<i>In Vitro</i> Activity of Tedizolid in Comparison with Other Oral and Intravenous Agents Against a Collection of Community-Acquired Methicillin-Resistant <i>Staphylococcus aureus</i> (2014â€“2015) in the United States. <i>Microbial Drug Resistance</i> , 2019, 25, 938-943.	2.0	9
15	Antimicrobial Resistance Surveillance and New Drug Development. <i>Open Forum Infectious Diseases</i> , 2019, 6, S5-S13.	0.9	10
16	Evaluation of the Bactericidal Activity of Fosfomycin in Combination with Selected Antimicrobial Comparison Agents Tested against Gram-Negative Bacterial Strains by Using Time-Kill Curves. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	35
17	Antimicrobial Activity Evaluation of Tebipenem (SPR859), an Orally Available Carbapenem, against a Global Set of Enterobacteriaceae Isolates, Including a Challenge Set of Organisms. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	27
18	Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of <i>Pseudomonas aeruginosa</i> from the United States, Europe, and China. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	35

#	ARTICLE	IF	CITATIONS
19	Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> . <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	11
20	Evaluation of the Revised Ceftaroline Disk Diffusion Breakpoints When Testing a Challenge Collection of Methicillin-Resistant <i>Staphylococcus aureus</i> Isolates. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	8
21	<i>In Vitro</i> Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	43
22	Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against <i>Aspergillus</i> spp. and 2 rare moulds. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 92, 43-45.	1.8	1
23	Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2400-2404.	3.0	50
24	Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	40
25	Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 101</i> <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	56
26	Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of <i>Candida</i> Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	65
27	WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant $\beta$ -lactamases. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1696-1703.	3.0	81
28	Activities of Omadacycline and Comparator Agents against <i>Staphylococcus aureus</i> Isolates from a Surveillance Program Conducted in North America and Europe. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	37
29	CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 352-358.	2.5	55
30	Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in <i>Candida albicans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	87
31	Enhanced activity of cefepime-tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 89, 305-309.	1.8	12
32	In Vitro Activity of Fosfomycin (ZTI-01, Fosfomycin for Injection) Against Contemporary Gram-Negative and Gram-Positive Isolates: A Comparison of Intermethod Testing. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	3
33	Comparison of BD Max StaphSR and BD Max MRSA <i>XT</i> for Screening of <i>Staphylococcus aureus</i> Clinical Isolates Collected from Hospitals in the United States. <i>Journal of Clinical Microbiology</i> , 2016, 54, 1668-1669.	3.9	1
34	Ceftaroline activity tested against viridans group streptococci from US hospitals. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 84, 232-235.	1.8	6
35	<i>In Vitro</i> Activity of Delafloxacin Tested against Isolates of <i>Streptococcus pneumoniae</i> , <i>Haemophilus influenzae</i> , and <i>Moraxella catarrhalis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6381-6385.	3.2	36
36	Effect of the $\beta$ -Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5454-5458.	3.2	121

#	ARTICLE	IF	CITATIONS
37	In vitro spectrum of pexiganan activity; bactericidal action and resistance selection tested against pathogens with elevated MIC values to topical agents. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 86, 66-69.	1.8	11
38	Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against <i>Candida</i> and <i>Aspergillus</i> spp., including echinocandin- and azole-resistant isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2868-2873.	3.0	85
39	<i>In vitro</i> antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 670-677.	3.0	150
40	Reproducibility of dalbavancin MIC test results and an updated surrogate accuracy analysis of vancomycin MIC values to infer dalbavancin susceptibility (2014). <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 86, 249-251.	1.8	4
41	Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013). <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 85, 200-204.	1.8	119
42	Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3174-3177.	3.2	14
43	Performance of BD Max StaphSR for Screening of Methicillin-Resistant <i>Staphylococcus aureus</i> Isolates among a Contemporary and Diverse Collection from 146 Institutions Located in Nine U.S. Census Regions: Prevalence of <i>mecA</i> Dropout Mutants. <i>Journal of Clinical Microbiology</i> , 2016, 54, 204-207.	3.9	15
44	<i>In Vitro</i> Spectrum of Pexiganan Activity When Tested against Pathogens from Diabetic Foot Infections and with Selected Resistance Mechanisms. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1751-1754.	3.2	59
45	Activity of Debio1452, a FabI Inhibitor with Potent Activity against <i>Staphylococcus aureus</i> and Coagulase-Negative <i>Staphylococcus</i> spp., Including Multidrug-Resistant Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2583-2587.	3.2	30
46	Validation of a Commercial Dry-Form Broth Microdilution Device (Sensititre) for Testing Tedizolid, a New Oxazolidinone. <i>Journal of Clinical Microbiology</i> , 2015, 53, 657-659.	3.9	8
47	<i>In Vitro</i> Activity of RX-P873 against Enterobacteriaceae, <i>Pseudomonas aeruginosa</i> , and <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2280-2285.	3.2	8
48	Arbekacin Activity against Contemporary Clinical Bacteria Isolated from Patients Hospitalized with Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3263-3270.	3.2	26
49	Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 83, 379-381.	1.8	33
50	Microbiological Assessment of Polymyxin B Components Tested Alone and in Combination. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7823-7825.	3.2	8
51	Post- $\beta$ -Lactamase-Inhibitor Effect of Tazobactam in Combination with Ceftolozane on Extended-Spectrum- $\beta$ -Lactamase-Producing Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2434-2437.	3.2	8
52	Serum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal disease. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 80, 327-329.	1.8	11
53	Potential Effects of Amikacin and Fosfomycin against Selected Amikacin-Nonsusceptible Gram-Negative Respiratory Tract Pathogens. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3714-3719.	3.2	39
54	Revised Reference Broth Microdilution Method for Testing Telavancin: Effect on MIC Results and Correlation with Other Testing Methodologies. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5547-5551.	3.2	42

#	ARTICLE	IF	CITATIONS
55	Amikacin-Fosfomycin at a Five-to-Two Ratio: Characterization of Mutation Rates in Microbial Strains Causing Ventilator-Associated Pneumonia and Interactions with Commonly Used Antibiotics. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3708-3713.	3.2	21
56	Isavuconazole and Nine Comparator Antifungal Susceptibility Profiles for Common and Uncommon <i>Candida</i> Species Collected in 2012: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values. <i>Mycopathologia</i> , 2014, 178, 1-9.	3.1	42
57	Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 Systemically active antifungal agents when tested against <i>Candida</i> spp.. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 79, 198-204.	1.8	64
58	Educational antimicrobial susceptibility testing as a critical component of microbiology laboratory proficiency programs: American Proficiency Institute results for 2007-2011. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 75, 357-360.	1.8	9
59	Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 636-639.	3.0	27
60	Evaluation of Vancomycin Susceptibility Testing for Methicillin-Resistant <i>Staphylococcus aureus</i> : Comparison of Etest and Three Automated Testing Methods. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2077-2081.	3.9	73
61	<i>In Vitro</i> Activities of Isavuconazole and Comparator Antifungal Agents Tested against a Global Collection of Opportunistic Yeasts and Molds. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2608-2616.	3.9	75
62	Use of a surfactant (polysorbate 80) to improve MIC susceptibility testing results for polymyxin B and colistin. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 74, 412-414.	1.8	65
63	Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, <i>Pseudomonas aeruginosa</i> , and <i>Bacteroides fragilis</i> Strains Having Various Resistance Phenotypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2390-2394.	3.2	112
64	Performance of Fusidic Acid (CEM-102) Susceptibility Testing Reagents: Broth Microdilution, Disk Diffusion, and Etest Methods as Applied to <i>Staphylococcus aureus</i> . <i>Journal of Clinical Microbiology</i> , 2010, 48, 972-976.	3.9	13
65	MIC Quality Control Guidelines and Disk Diffusion Test Optimization for CEM-101, a Novel Fluoroketolide. <i>Journal of Clinical Microbiology</i> , 2010, 48, 1470-1473.	3.9	2
66	Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 537-543.	2.5	43
67	Spectrum of activity, mutation rates, synergistic interactions, and the effects of pH and serum proteins for fusidic acid (CEM-102). <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 66, 301-307.	1.8	20
68	<i>Escherichia coli</i> resistance to quinolones at a comprehensive cancer center. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 67, 266-269.	1.8	27
69	Nine-Hospital Study Comparing Broth Microdilution and Etest Method Results for Vancomycin and Daptomycin against Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3162-3165.	3.2	87
70	Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007). <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 65, 331-334.	1.8	41
71	Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 65, 414-426.	1.8	156
72	Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 63, 415-425.	1.8	22

#	ARTICLE	IF	CITATIONS
73	In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant <i>Staphylococcus aureus</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 60, 399-403.	1.8	21
74	Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 60, 441-444.	1.8	33
75	Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 61, 203-213.	1.8	55
76	Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 1092-1098.	3.0	44
77	Rapid Emergence of <i>bla</i> <sub>CTX-M</sub> Among Enterobacteriaceae in U.S. Medical Centers: Molecular Evaluation from the MYSTIC Program (2007). <i>Microbial Drug Resistance</i> , 2008, 14, 211-216.	2.0	79
78	Antimicrobial Activity of Omiganan Pentahydrochloride against Contemporary Fungal Pathogens Responsible for Catheter-Associated Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1187-1189.	3.2	43
79	Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 57, 207-215.	1.8	47
80	Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006). <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 59, 425-432.	1.8	36
81	Clonal occurrences of multidrug-resistant Gram-negative bacilli: report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States (2004). <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 54, 249-257.	1.8	20
82	Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA). <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 56, 57-62.	1.8	73
83	Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: Report from the MYSTIC Program (1999-2005). <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 56, 367-372.	1.8	124
84	Carbapenem Susceptibility Discords among <i>Acinetobacter</i> Isolates. <i>Clinical Infectious Diseases</i> , 2006, 42, 158-158.	5.8	22
85	Reproducibility assessment of tigecycline MIC results by broth microdilution methods using commercially prepared dry-form panels. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 52, 67-69.	1.8	0
86	Reproducibility of daptomycin MIC results using dry-form commercial trays with appropriate supplemental calcium content. <i>International Journal of Antimicrobial Agents</i> , 2005, 25, 274-275.	2.5	3
87	Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, 290-296.	3.0	95
88	Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres. <i>International Journal of Antimicrobial Agents</i> , 2004, 23, 52-59.	2.5	34
89	Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: Report of year five (2003). <i>Diagnostic Microbiology and Infectious Disease</i> , 2004, 49, 273-281.	1.8	25
90	Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates. <i>Diagnostic Microbiology and Infectious Disease</i> , 2004, 50, 73-75.	1.8	44



#	ARTICLE	IF	CITATIONS
91	Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America. <i>Diagnostic Microbiology and Infectious Disease</i> , 2003, 47, 365-372.	1.8	54
92	Molecular Epidemiology of Macrolide Resistance in Neonatal Bloodstream Isolates of Group B Streptococci. <i>Journal of Clinical Microbiology</i> , 2003, 41, 2659-2661.	3.9	42
93	Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 157-161.	3.0	20
94	Commercial Broth Microdilution Panel Validation and Reproducibility Trials for Garenoxacin (BMS-284756), a Novel Desfluoroquinolone. <i>Journal of Clinical Microbiology</i> , 2003, 41, 3967-3969.	3.9	4
95	Fluoroquinolone Resistance in <i>Streptococcus pneumoniae</i> in United States since 1994-1995. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 680-688.	3.2	137
96	Tiamulin Activity against Fastidious and Nonfastidious Veterinary and Human Bacterial Isolates: Initial Development of In Vitro Susceptibility Test Methods. <i>Journal of Clinical Microbiology</i> , 2002, 40, 461-465.	3.9	23
97	A comparison of the antimicrobial activity of meropenem and selected broad-spectrum antimicrobials tested against multi-drug resistant Gram-negative bacilli including bacteraemic <i>Salmonella</i> spp.. <i>International Journal of Antimicrobial Agents</i> , 2002, 20, 426-431.	2.5	31
98	In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of <i>Mycobacterium marinum</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2002, 42, 145-147.	1.8	35
99	Antimicrobial susceptibility patterns of $\hat{I}^2$ -hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997-2000). <i>Diagnostic Microbiology and Infectious Disease</i> , 2002, 43, 157-162.	1.8	70
100	Evaluation of the in vitro activity of six broad-spectrum $\hat{I}^2$ -lactam antimicrobial agents tested against recent clinical isolates from India: a survey of ten medical center laboratories. <i>Diagnostic Microbiology and Infectious Disease</i> , 2002, 44, 367-377.	1.8	59
101	Activity of BMS284756 (T-3811) tested against anaerobic bacteria, <i>Campylobacter jejuni</i> , <i>Helicobacter pylori</i> and <i>Legionella</i> spp.. <i>Diagnostic Microbiology and Infectious Disease</i> , 2001, 40, 45-49.	1.8	18
102	Comparative Bactericidal Activities of Ciprofloxacin, Clinafloxacin, Grepafloxacin, Levofloxacin, Moxifloxacin, and Trovafloxacin against <i>Streptococcus pneumoniae</i> in a Dynamic In Vitro Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 673-678.	3.2	47
103	Antimicrobial Resistance among Clinical Isolates of <i>Streptococcus pneumoniae</i> in the United States during 1999-2000, Including a Comparison of Resistance Rates since 1994-1995. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1721-1729.	3.2	523
104	Group B streptococci causing neonatal bloodstream infection: Antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere. <i>American Journal of Obstetrics and Gynecology</i> , 2000, 183, 859-862.	1.3	103
105	Molecular Characterization of the $\hat{I}^2$ -Lactamases from Clinical Isolates of <i>Moraxella</i> ( <i>Branhamella</i> ) <i>catarrhalis</i> Obtained from 24 U.S. Medical Centers during 1994-1995 and 1997-1998. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 444-446.	3.2	25
106	In Vitro Activity of ABT-773, a New Ketolide, against Recent Clinical Isolates of <i>Streptococcus pneumoniae</i> , <i>Haemophilus influenzae</i> , and <i>Moraxella catarrhalis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 447-449.	3.2	49
107	Antimicrobial Resistance with <i>Streptococcus pneumoniae</i> in the United States, 1997-98. <i>Emerging Infectious Diseases</i> , 1999, 5, 757-765.	4.3	188
108	Persistence of <i>Legionella Pneumophilum</i> in a Hospital's Water System: A 13-Year Survey. <i>Infection Control and Hospital Epidemiology</i> , 1999, 20, 793-797.	1.8	66

#	ARTICLE	IF	CITATIONS
109	A 1997-1998 national surveillance study: <i>Moraxella catarrhalis</i> and <i>Haemophilus influenzae</i> antimicrobial resistance in 34 US institutions. <i>International Journal of Antimicrobial Agents</i> , 1999, 13, 99-107.	2.5	39
110	Comparative evaluation of etest for susceptibility testing <i>Neisseria meningitidis</i> with eight antimicrobial agents An investigation using U.S. food and drug administration regulatory criteria. <i>Diagnostic Microbiology and Infectious Disease</i> , 1997, 27, 93-97.	1.8	11
111	Application of the Etest to antimicrobial susceptibility testing of <i>Legionella</i> spp.. <i>Diagnostic Microbiology and Infectious Disease</i> , 1994, 19, 175-178.	1.8	22
112	Comparison of identification systems for <i>Staphylococcus epidermidis</i> and other coagulase-negative <i>Staphylococcus</i> species. <i>Diagnostic Microbiology and Infectious Disease</i> , 1994, 18, 151-155.	1.8	36
113	Evaluations of the etest for antimicrobial susceptibility testing of <i>Legionella pneumophila</i> , including validation of the imipenem and sparfloxacin strips. <i>Diagnostic Microbiology and Infectious Disease</i> , 1994, 20, 159-162.	1.8	14
114	Antifungal activity of a new triazole, D0870, compared with four other antifungal agents tested against clinical isolates of <i>Candida</i> and <i>Torulopsis glabrata</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 1994, 19, 75-80.	1.8	24